Hennion & Walsh Asset Management Inc. Invests $1.19 Million in Indivior PLC (NASDAQ:INDV)

Hennion & Walsh Asset Management Inc. bought a new position in Indivior PLC (NASDAQ:INDV) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 95,935 shares of the company’s stock, valued at approximately $1,192,000. Hennion & Walsh Asset Management Inc. owned approximately 0.07% of Indivior at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the company. Iron Triangle Partners LP acquired a new position in Indivior in the 3rd quarter valued at approximately $8,243,000. Krensavage Asset Management LLC acquired a new position in Indivior during the third quarter valued at approximately $6,843,000. Millennium Management LLC lifted its stake in shares of Indivior by 48.1% in the second quarter. Millennium Management LLC now owns 493,313 shares of the company’s stock worth $7,952,000 after buying an additional 160,282 shares during the last quarter. Stonepine Capital Management LLC bought a new stake in shares of Indivior during the 3rd quarter worth $2,632,000. Finally, Clark Estates Inc. NY acquired a new position in Indivior during the 3rd quarter worth $2,477,000. 60.33% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the company. Piper Sandler reiterated an “overweight” rating and issued a $16.00 price objective (up from $15.00) on shares of Indivior in a research note on Friday, October 25th. Craig Hallum dropped their price target on Indivior from $20.00 to $16.00 and set a “buy” rating on the stock in a research report on Friday, October 11th.

Indivior Stock Down 0.1 %

Shares of INDV opened at $11.65 on Friday. Indivior PLC has a 12-month low of $7.33 and a 12-month high of $23.22. The firm has a market capitalization of $1.61 billion, a price-to-earnings ratio of -291.18 and a beta of 0.74. The stock’s 50-day moving average price is $11.46 and its 200 day moving average price is $11.07.

Indivior (NASDAQ:INDV) last announced its quarterly earnings data on Thursday, October 24th. The company reported $0.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.15. The company had revenue of $307.00 million during the quarter, compared to analysts’ expectations of $302.25 million. Indivior had a negative net margin of 0.17% and a negative return on equity of 351.08%. Equities research analysts expect that Indivior PLC will post 1.62 EPS for the current year.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.